ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1544-1553

  Munshi, Neru ^b   Jeay, Sébastien ^a,c   Li, Youzhi ^b   Chen, Chang Rung ^a   France, Dennis S ^a   Ashwell, Mark A ^a   Hill, Jason ^a   Moussa, Magdi M ^a   Leggett, David S ^b   Li, Chiang J ^b  

^a ARQULE INC   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5,6 DIHYDRO 4H PYRROLO[3,2,1 IJ]QUINOLIN 1 YL) 4 (1H INDOL 3 YL)PYRROLIDINE 2,5 DIONE; ANTINEOPLASTIC AGENT; ARQ 197; CASPASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOSUPPRESSION; MICE; MICE, NUDE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLES; PYRROLIDINONES; QUINOLINES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953458271     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1173     Document Type: Article

References (43)

1. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
2. Gherardi E, Stoker M. Hepatocytes and scatter factor. Nature 1990;346:228.
3. Naldini L, Weidner KM, Vigna E, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78. (Pubitemid 21905304)
4. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci U S A 1991;88:7001-5.
5. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998;8:404-10. (Pubitemid 28458706)
6. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991;6:1997-2003. (Pubitemid 21924039)
7. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993;123:223-35. (Pubitemid 23284877)
8. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
9. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
10. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33. (Pubitemid 14065275)
11. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45. (Pubitemid 44140861)
12. Boccaccio C, Sabatino G, Medico E, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005;434:396-400. (Pubitemid 40469184)
13. Kammula US, Kuntz EJ, Francone TD, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248:219-28.
14. Takayama H, LaRochelle WJ, Sharp R, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 1997;94:701-6. (Pubitemid 27053697)
15. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109:863-7. (Pubitemid 34275106)
16. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-902. (Pubitemid 29202761)
17. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73. (Pubitemid 27198158)
18. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002;16:108-10.
19. Firon M, Shaharabany M, Altstock RT, et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 2000;19:2386-97. (Pubitemid 30323471)
20. Furge KA, Kiewlich D, Le P, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A 2001;98:10722-7.
21. Herynk MH, Stoeltzing O, Reinmuth N, et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003;63:2990-6. (Pubitemid 36667174)
22. Jiang WG, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001;7:2555-62. (Pubitemid 32751662)
23. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 2003;9:5161-70. (Pubitemid 37420030)
24. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73. (Pubitemid 38903162)
25. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045-54. (Pubitemid 29012208)
26. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001;61:7518-24. (Pubitemid 32995042)
27. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9. (Pubitemid 43259957)
28. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001;98:7443-8. (Pubitemid 32567968)
29. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-9.
30. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26. (Pubitemid 40732764)
31. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21:4885-93.
32. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9. (Pubitemid 37139865)
33. Wang X, Le P, Liang C, et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther 2003;2:1085-92.
34. Al Awar RS, Ray JE, Hecker KA, et al. 1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 2004;14:3217-20.
35. Hays JL, Watowich SJ. Oligomerization-induced modulation of TPR-MET tyrosine kinase activity. J Biol Chem 2003;278:27456-63.
36. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-92.
37. Underiner TL, Herbertz T, Miknyoczki SJ. Discovery of small molecule c-Met inhibitors: evolution and profiles of clinical candidates. Anticancer Agents Med Chem 2010;10:7-27.
38. Pan BS, Chan GK, Chenard M, et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res 2010;70:1524-33.
39. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275:8806-11. (Pubitemid 30180235)
40. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21. (Pubitemid 43271667)
41. Mekhail T, Rich L, Rosen L. Final results: a dose escalation phase 1 study of ARQ 197, a selective c-Met inhibitor, in patients with metatstatic solid tumors. J Clin Oncol 2009;27:Abstract 3548.
42. Yap TA, Frentzas S, Tunariu N. Final results of a pharmacokinetic and pharmacodynamic phase I trial of ARQ 197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the anti-angiogenic activity of selective c-Met inhibition. J Clin Oncol 2009;27:Abstract 3523.
43. Laux I, Goldman J, Just R. Phase 1 dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol 2009;27:Abstract 3549.